F M Investments LLC Sells 8,220 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

F M Investments LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 29.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,107 shares of the medical research company's stock after selling 8,220 shares during the period. F M Investments LLC's holdings in Thermo Fisher Scientific were worth $10,460,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock valued at $17,297,426,000 after buying an additional 196,864 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after buying an additional 197,442 shares during the last quarter. Norges Bank acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $3,149,754,000. Franklin Resources Inc. lifted its stake in Thermo Fisher Scientific by 5.7% in the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock valued at $2,935,377,000 after purchasing an additional 262,062 shares during the last quarter. Finally, Amundi boosted its stake in shares of Thermo Fisher Scientific by 13.5% during the 4th quarter. Amundi now owns 2,860,847 shares of the medical research company's stock worth $1,556,689,000 after acquiring an additional 340,263 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Remove Ads

Insider Activity

In related news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,900 shares of company stock valued at $13,106,062. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $8.20 during trading on Tuesday, hitting $441.13. 1,087,827 shares of the company were exchanged, compared to its average volume of 1,699,332. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 1-year low of $409.85 and a 1-year high of $627.88. The company has a market capitalization of $166.42 billion, a P/E ratio of 26.69, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The business's 50 day moving average is $507.90 and its 200-day moving average is $537.62.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 10.41%.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Scotiabank increased their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research report on Monday, February 3rd. Royal Bank of Canada set a $693.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 31st. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Finally, Wells Fargo & Company raised their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.